Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 38 Publications

Nature, 2016, 538(7626):477-482

PubMed: 27760111

Blood, 2013, 121(10):1850-7

PubMed: 23303820

Blood, 2013, 122(9):1587-98

PubMed: 23881917

Blood, 2011, 117(26):7145-54

PubMed: 21562047

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444

Leukemia, 2016, 30(2):351-60

PubMed: 26488112

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651

Chem Sci, 2014, 5, 2794–2803

PubMed:
Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075

Cell Death Dis, 2013, 4:e883

PubMed: 24157877

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469
Frontiers in Oncology, 2015, 4:368

PubMed: 25566506

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126

Open Biol, 2015, 5(3)

PubMed: 25761368

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320

PLoS One, 2011, 6(9):e24590

PubMed: 21931768

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278
Microvasc Res, 2015, 101:72-81

PubMed: 26122935

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

13 Customer Reviews

KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.
ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

(A) In vitro generated Mcl-1-deleted Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM. p185+ Arf-/- cells serve as a control. (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or (E) IM or (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

Navitoclax (ABT-263) purchased from Selleck.
Human Ph+ cell lines: (A) OP-1 Ph+ B-ALL (B) TOM1 Ph+ B-ALL and (C) BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL. For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M2PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2wTWM2OD1yLkCwOlY6KM7:TR?=	NHvxZmhUSU6JRWK=
MV-4-11	NXPLZlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlv0TWM2OD1yLkCxOVg3KM7:TR?=	NYqzeplKW0GQR1XS
NKM-1	NYi2dIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMEG2PVkh\|ryP	MlfuV2FPT0WU
ML-2	NEXzSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{flNGlEPTB;MD6wNVk5OyEQvF2=	NWPS[HlGW0GQR1XS
BV-173	M4j0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInHclNKSzVyPUCuNFI{OTRizszN	MnzYV2FPT0WU
RS4-11	MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPmT45NUUN3ME2wMlAzPTh5IN88US=>	MoD4V2FPT0WU
HL-60	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[zTWM2OD1yLkCyPVA5KM7:TR?=	MWPTRW5ITVJ?
KY821	NI\ubZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2C5UmlEPTB;MD6wNlk4PSEQvF2=	NEjGOXRUSU6JRWK=
ECC10	M3j6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG5OIlsUUN3ME2wMlA{Pzl{IN88US=>	M1vDZ3NCVkeHUh?=
NCI-H720	NYnaZppoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknuTWM2OD1yLkC0NFEyKM7:TR?=	NF\ZbWJUSU6JRWK=
QIMR-WIL	M2nLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMESyPFch\|ryP	M1\EVnNCVkeHUh?=
KG-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[xZWlEPTB;MD6wOFQ5PiEQvF2=	NUHr[WlLW0GQR1XS
TGW	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[2NZY1UUN3ME2wMlA1PjN\|IN88US=>	M3TITXNCVkeHUh?=
ATN-1	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvmTWM2OD1yLkC0O\|M{KM7:TR?=	NEPJdIlUSU6JRWK=
RH-18	NV:2[JBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHkc3EyUUN3ME2wMlA3ODR6IN88US=>	Mk\rV2FPT0WU
EW-18	NYXVfXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{P1[2lEPTB;MD6wOlg1OSEQvF2=	NGrV[llUSU6JRWK=
NB17	M2fFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTRd\|M3UUN3ME2wMlA4OTJ2IN88US=>	M3rXbXNCVkeHUh?=
SK-NEP-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPYNFNYUUN3ME2wMlA4OjF\|IN88US=>	NVrDd2dvW0GQR1XS
P12-ICHIKAWA	NGW4U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nwWmlEPTB;MD6wO\|c4QCEQvF2=	NGW5UYRUSU6JRWK=
KARPAS-45	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nLVGlEPTB;MD6wO\|gyPSEQvF2=	MX7TRW5ITVJ?
EW-3	NVjTTW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MliwTWM2OD1yLkC4NFU{KM7:TR?=	MWrTRW5ITVJ?
NB13	M4XkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrQTWM2OD1yLkC4NlA{KM7:TR?=	NFe3[3VUSU6JRWK=
NCI-H209	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf5d3pOUUN3ME2wMlA5PzB2IN88US=>	NG\V[YZUSU6JRWK=
NCI-H1092	M1nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO3[HRKSzVyPUCuNVAzPzVizszN	NYjV[ZEyW0GQR1XS
NH-12	NGnZdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMUC3OFQh\|ryP	NIXS[3ZUSU6JRWK=
697	NV3WUo9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\NSGlEPTB;MD6xNFg{QSEQvF2=	M{T3OXNCVkeHUh?=
KE-37	M1S1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknyTWM2OD1yLkGxN\|ch\|ryP	NH7XdI5USU6JRWK=
MOLT-4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfDXmhKSzVyPUCuNVUyPjlizszN	MWnTRW5ITVJ?
CHP-134	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Pu[2lEPTB;MD6xOlMxPiEQvF2=	NELVPXBUSU6JRWK=
D-283MED	NXfIOnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInhNZVKSzVyPUCuNVc3QDZizszN	M{j4TXNCVkeHUh?=
LU-135	M1\ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LFdWlEPTB;MD6xPFU2OiEQvF2=	M3Hte3NCVkeHUh?=
LU-134-A	M1;2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHrTWM2OD1yLkG4OlcyKM7:TR?=	NIra[W5USU6JRWK=
EM-2	NYXv[5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rQTGlEPTB;MD6xPVkyQCEQvF2=	M2O0dHNCVkeHUh?=
LU-139	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LoSGlEPTB;MD6yNFQ6QCEQvF2=	NE[4OGFUSU6JRWK=
ALL-PO	M{fo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3qZ3BKSzVyPUCuNlE6QDhizszN	MY\TRW5ITVJ?
NB12	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDHc3pKSzVyPUCuNlMyOTVizszN	MlTBV2FPT0WU
KP-N-YN	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H5bmlEPTB;MD6yN\|U4OyEQvF2=	MUfTRW5ITVJ?
BEN	NX3xTY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMkO5Olgh\|ryP	MXrTRW5ITVJ?
HCC1569	NITGSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvrS2NKSzVyPUCuNlUyODZizszN	Mkm4V2FPT0WU
HuO9	NEHsb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPVNmw1UUN3ME2wMlI3PzF3IN88US=>	NVX0RWpYW0GQR1XS
WM-115	NVrYPZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnZRoFKSzVyPUCuNlc4OzhizszN	MVjTRW5ITVJ?
CCRF-CEM	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwM{O1Nlkh\|ryP	M1TxOHNCVkeHUh?=
IST-SL1	NWHWTHluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwM{WzOFMh\|ryP	NGjoT\|FUSU6JRWK=
BE-13	NVnPOnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XzdmlEPTB;MD6zOlQ2QSEQvF2=	M1\5VXNCVkeHUh?=
COR-L88	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vCV2lEPTB;MD6zOlU1KM7:TR?=	MXXTRW5ITVJ?
DOHH-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNEGwNlMh\|ryP	MnXiV2FPT0WU
A704	NFP4R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNEK2O{DPxE1?	M4f4e3NCVkeHUh?=
KNS-81-FD	NYPPbWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjLUXRKSzVyPUCuOFQxOTdizszN	NWDXS5puW0GQR1XS
RPMI-8226	NXzHWJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXmxTndSUUN3ME2wMlQ2PjV{IN88US=>	NGDPclZUSU6JRWK=
TGBC24TKB	NX\hUoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNEW3O\|gh\|ryP	NIXGcpZUSU6JRWK=
NCI-H1304	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH4R3hKSzVyPUCuOFYyPTdizszN	M{PHOHNCVkeHUh?=
MOLT-13	NEDKRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwNE[2NVMh\|ryP	NV;BWFVYW0GQR1XS
EW-22	NF\6eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jxVGlEPTB;MD60OlY4OSEQvF2=	NUjWR4JzW0GQR1XS
MS-1	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwNE[5N\|Mh\|ryP	MlvMV2FPT0WU
RMG-I	MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXETWM2OD1yLkS5OFY1KM7:TR?=	Moi5V2FPT0WU
NTERA-S-cl-D1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1q1R2lEPTB;MD61NFAyQSEQvF2=	NV7TUI8zW0GQR1XS
NCI-H1048	NGLIVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwNUC5OVMh\|ryP	NWH5[2ZIW0GQR1XS
SW1417	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwNUW0N\|gh\|ryP	M4LaeXNCVkeHUh?=
DB	NHTreoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXGwc4R[UUN3ME2wMlU4ODhizszN	MXLTRW5ITVJ?
MEG-01	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNUizNkDPxE1?	M2HHSnNCVkeHUh?=
EW-13	NWrnd\|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfaWldQUUN3ME2wMlU5OzRzIN88US=>	Mo\NV2FPT0WU
LAMA-84	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj5SmxKSzVyPUCuOVkzODdizszN	NFrmPJBUSU6JRWK=
J-RT3-T3-5	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNkC4NFgh\|ryP	M1TzbnNCVkeHUh?=
MOLT-16	M17pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[0XmlEPTB;MD62OVI3PCEQvF2=	NUnYPY5vW0GQR1XS
DU-4475	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzmTWM2OD1yLk[1OFI4KM7:TR?=	M4LGSHNCVkeHUh?=
HAL-01	NH\pfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\xTWM2OD1yLkeyOVQ6KM7:TR?=	NGjDU25USU6JRWK=
RD	M3TaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTtRmRRUUN3ME2wMlc2QDl7IN88US=>	NX7aWmt3W0GQR1XS
OAW-28	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwN{izO{DPxE1?	M4fzZ3NCVkeHUh?=
HCC38	NFvmbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HTXmlEPTB;MD64NFE6KM7:TR?=	M1zyfXNCVkeHUh?=
NMC-G1	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7hc2lKSzVyPUCuPFEyOjFizszN	Ml7tV2FPT0WU
EW-16	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHnTWM2OD1yLkixN\|I5KM7:TR?=	Ml7ZV2FPT0WU
DU-145	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzqTWM2OD1yLki5PVI{KM7:TR?=	MX3TRW5ITVJ?
HPAF-II	M1jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwOUK2Nlgh\|ryP	MXzTRW5ITVJ?
A427	NGX1cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7vS\|VtUUN3ME2wMlk{ODJ{IN88US=>	MlrFV2FPT0WU
PA-1	NXHhVFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwOUW2OFIh\|ryP	NVfjdlFIW0GQR1XS
OAW-42	NYD5S2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfqTWM2OD1yLkm2NVQ3KM7:TR?=	MY\TRW5ITVJ?
L-428	M1;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFwMEGyOUDPxE1?	MYXTRW5ITVJ?
COLO-824	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwMEG3NFgh\|ryP	Mmq1V2FPT0WU
P30-OHK	M4rLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\GVGlEPTB;MT6wOFY5QCEQvF2=	NF\1XVlUSU6JRWK=
NCI-H2170	NYjKXZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\Ce2lEPTB;MT6wOlI{KM7:TR?=	NFHOWWtUSU6JRWK=
HCC2998	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTFwMEexN\|Uh\|ryP	NILBRZpUSU6JRWK=
NB14	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTsXJF{UUN3ME2xMlE{PzR6IN88US=>	NXz6eHpwW0GQR1XS
TGBC1TKB	NWfIeHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofrTWM2OD1zLkG0NVUzKM7:TR?=	NWXSd2ozW0GQR1XS
KP-N-YS	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlX0TWM2OD1zLkG2NlM3KM7:TR?=	M2TDcXNCVkeHUh?=
CAL-120	M2T5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TzXGlEPTB;MT6xOlQzQSEQvF2=	Mm[4V2FPT0WU
SBC-1	NFHNN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTFwMUmwOVMh\|ryP	Ml\sV2FPT0WU
C32	NH22VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPxZXNWUUN3ME2xMlE6ODh6IN88US=>	MVTTRW5ITVJ?
HCC2157	M4H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwMUm0PVQh\|ryP	NX\sWGdoW0GQR1XS
COLO-792	NEK4UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVWySoVLUUN3ME2xMlIxODdzIN88US=>	NYrDZpdsW0GQR1XS
ES7	M13vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHhbGZ5UUN3ME2xMlI4QTVzIN88US=>	MWPTRW5ITVJ?
HEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFwM{GwNlkh\|ryP	MknDV2FPT0WU
ES4	MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTDb2lKSzVyPUGuN\|Q6QThizszN	MmO5V2FPT0WU
NCI-SNU-1	M13iTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDDR4k3UUN3ME2xMlM3PTV3IN88US=>	MkjsV2FPT0WU
MDA-MB-415	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jubmlEPTB;MT6zPFg2KM7:TR?=	M{LsdHNCVkeHUh?=
NCI-H2342	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTFwNECyOlkh\|ryP	MVnTRW5ITVJ?
NB69	NXLJeo54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTJOnJmUUN3ME2xMlQ3OjdzIN88US=>	M2Tt[HNCVkeHUh?=
D-247MG	NY\YUmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;0NGlEPTB;MT61NVEzOiEQvF2=	MlLyV2FPT0WU
SCC-4	NWi1ZnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTFwNUm4PFch\|ryP	MVjTRW5ITVJ?
HuH-7	NFLyWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFwNkeyPVMh\|ryP	M{LocnNCVkeHUh?=
A388	NGHvdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTFwNki3NlQh\|ryP	NVfncYJZW0GQR1XS
Calu-3	NVPFO5BTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHNTWM2OD1zLkewOlk4KM7:TR?=	NHrTcohUSU6JRWK=
NCI-H1648	NUnuN2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3se4lsUUN3ME2xMlcyPDF6IN88US=>	NXe4TXJIW0GQR1XS
NCI-H2052	NHvqbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnuyTWM2OD1zLkeyNlAyKM7:TR?=	M{TmSHNCVkeHUh?=
Ramos-2G6-4C10	NH7KWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHvbI1KSzVyPUGuO\|M3PTZizszN	NWSxT\|huW0GQR1XS
DEL	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LJSGlEPTB;MT63OFY6OiEQvF2=	NH7DdZVUSU6JRWK=
SNU-423	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTFwN{ixOVch\|ryP	MWTTRW5ITVJ?
COR-L23	M4TYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu1TVJ4UUN3ME2xMlc6QDd2IN88US=>	M2TlT3NCVkeHUh?=
OMC-1	NHPGcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3qxcWlEPTB;MT64OlAyPiEQvF2=	NYr0Vo93W0GQR1XS
EW-11	NHy3UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7tTWM2OD1zLkm1OlU4KM7:TR?=	NYTQPJBvW0GQR1XS
HSC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[yNWxKSzVyPUGuPVY{PjVizszN	M4ro[HNCVkeHUh?=
MLMA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVe3e3JuUUN3ME2xMlk3Pjd5IN88US=>	MVnTRW5ITVJ?
RCM-1	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nMfGlEPTB;Mj6wNFM6QSEQvF2=	M3yyVXNCVkeHUh?=
MFE-280	M1n5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXaTWM2OD1{LkCyPFQ5KM7:TR?=	MULTRW5ITVJ?
ES8	M1;JOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnZWIFKSzVyPUKuNlU1PzFizszN	NIexUppUSU6JRWK=
TE-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\mbY1bUUN3ME2yMlI6PDd\|IN88US=>	MlvRV2FPT0WU
HuO-3N1	NGXuTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHsW2N{UUN3ME2yMlQ5PzhizszN	MmHBV2FPT0WU
MHH-NB-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJwNUGxOVgh\|ryP	NIPkclRUSU6JRWK=
TGBC11TKB	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rkTWlEPTB;Mj61O\|Y5OSEQvF2=	MX3TRW5ITVJ?
HOP-92	NH23VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j0e2lEPTB;Mj61PFc1OyEQvF2=	MXTTRW5ITVJ?
IGR-1	NYrPTlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S1b2lEPTB;Mj62NlA{PSEQvF2=	NFzCZWxUSU6JRWK=
GOTO	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LvSmlEPTB;Mj62OVM4PyEQvF2=	M1rtU3NCVkeHUh?=
NCI-H1650	M4PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjXTnNKSzVyPUKuO\|IzOTVizszN	NHHscHZUSU6JRWK=
NCI-H1581	M1X3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX1TWM2OD1{Lke5OlgyKM7:TR?=	MXzTRW5ITVJ?
NCI-H2405	NF;oZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G0W2lEPTB;Mj64Nlc5OiEQvF2=	NH3YVmJUSU6JRWK=
U-118-MG	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvv[pA3UUN3ME2yMlk3PDlzIN88US=>	Mn[3V2FPT0WU
DoTc2-4510	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTrTWM2OD1\|LkCxOFE4KM7:TR?=	MYHTRW5ITVJ?
NCI-H596	NHTNeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTNwMES5PVch\|ryP	MWnTRW5ITVJ?
MPP-89	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj1SWc4UUN3ME2zMlA2PjZ4IN88US=>	NG\OTXlUSU6JRWK=
GCIY	M2rJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[2dGlEPTB;Mz6yNFQ6OSEQvF2=	NVu2VY5GW0GQR1XS
SW626	NFvQfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnDflNIUUN3ME2zMlI1PTR\|IN88US=>	M{KwenNCVkeHUh?=
OCI-AML2	M1TWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDDPJY6UUN3ME2zMlMyOjd{IN88US=>	NEL1e5pUSU6JRWK=
NBsusSR	NYj0OnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnLTWM2OD1\|LkO0PVM5KM7:TR?=	MmfuV2FPT0WU
AN3-CA	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[wTWM2OD1\|LkS0NlM5KM7:TR?=	NHXmbJFUSU6JRWK=
EFM-19	NEjPd\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7tbXdEUUN3ME2zMlQ5OzN7IN88US=>	M33JWXNCVkeHUh?=
RVH-421	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLBSXlyUUN3ME2zMlU3QDd5IN88US=>	Mly0V2FPT0WU
5637	NYr3U2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jZfmlEPTB;Mz62NVExOyEQvF2=	NHnTSpJUSU6JRWK=
PANC-08-13	NID0RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTNwNkO0O\|Ih\|ryP	MmPvV2FPT0WU
H9	NWLwcXExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTXXoZKSzVyPUOuOlcyPDRizszN	NH:0N4xUSU6JRWK=
KARPAS-299	NH\3[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\RVIFWUUN3ME2zMlY4OzZzIN88US=>	NUTFOXJDW0GQR1XS
TE-5	M2ewdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTNwN{C3NFkh\|ryP	Mn;QV2FPT0WU
NOS-1	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTNwN{m4N\|Qh\|ryP	NYXMdnlMW0GQR1XS
HH	NVvBb3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnWNGRKSzVyPUOuPFM5PjhizszN	MUTTRW5ITVJ?
769-P	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfwdGhKSzVyPUOuPFk2OSEQvF2=	MUjTRW5ITVJ?
CHP-212	NEPlTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHSVml[UUN3ME2zMlkzPTR7IN88US=>	MmrRV2FPT0WU
NCI-H82	M3XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnMcmdKSzVyPUOuPVU6OzZizszN	MXrTRW5ITVJ?
Mo-T	NFHsXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLKdXFLUUN3ME20MlA1OzF{IN88US=>	M33HSHNCVkeHUh?=
BB65-RCC	NXu1b2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTRwMESzPVkh\|ryP	NHTKN4VUSU6JRWK=
SW1990	NVG0V\|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrpbIJKSzVyPUSuNFU6ODhizszN	MXfTRW5ITVJ?
LK-2	NXvVcJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTRwMUGyPVMh\|ryP	M2DlWXNCVkeHUh?=
ES5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfZc2hKSzVyPUSuNVM6QDVizszN	NXrnVmNoW0GQR1XS
JVM-3	NEXOTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3IbnBXUUN3ME20MlE5OjJ{IN88US=>	MVTTRW5ITVJ?
RPMI-7951	NFPKVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PhXGlEPTB;ND6yNlQyOyEQvF2=	Mkf4V2FPT0WU
Calu-6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LtdGlEPTB;ND6yO\|g5OSEQvF2=	M4jYUHNCVkeHUh?=
LC-2-ad	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzITWM2OD12LkK5OVY5KM7:TR?=	NGnJSnlUSU6JRWK=
SW954	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;tTWM2OD12LkK5OlYh\|ryP	MUXTRW5ITVJ?
H-EMC-SS	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTRwM{G4N\|Eh\|ryP	NFXifoxUSU6JRWK=
ES3	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3PXpdKSzVyPUSuN\|U1PDFizszN	NWe0NlE2W0GQR1XS
no-11	NEP4bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPSTWM2OD12LkO1OVU1KM7:TR?=	MnzWV2FPT0WU
LAN-6	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXlZm9NUUN3ME20MlQ2OTh7IN88US=>	NYG1dmFbW0GQR1XS
FTC-133	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jRSGlEPTB;ND61N\|k2KM7:TR?=	MULTRW5ITVJ?
8505C	NH\jPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTRwNUSyN{DPxE1?	MlviV2FPT0WU
SW620	NV;P[mdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\RTWM2OD12LkW3NFU4KM7:TR?=	M4i3dXNCVkeHUh?=
BCPAP	NFzKTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL5VodbUUN3ME20MlY{PDhzIN88US=>	NWjl[GFEW0GQR1XS
SK-LU-1	NYTIdG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrrTWM2OD12Lk[2NFg6KM7:TR?=	NFLhUVdUSU6JRWK=
NCI-H1623	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInobHRKSzVyPUSuO\|AzOjhizszN	M1vibnNCVkeHUh?=
C2BBe1	NUj3e4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzYWHE6UUN3ME20Mlc1ODB6IN88US=>	M3nKXHNCVkeHUh?=
GP5d	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XWNWlEPTB;ND63PFM5QCEQvF2=	MXfTRW5ITVJ?
NB6	M{LMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPMTWM2OD12Lki2NlA1KM7:TR?=	NXXZcWRuW0GQR1XS
MDA-MB-157	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2X2UmlEPTB;ND64PFc3KM7:TR?=	M2Dve3NCVkeHUh?=
UMC-11	NV3DNGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rGdmlEPTB;ND64PFk3PCEQvF2=	NWfvb2JUW0GQR1XS
HCC1419	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TxO2lEPTB;ND65NFA3OyEQvF2=	NYfZTIsxW0GQR1XS
NCI-H2029	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nGVmlEPTB;ND65OFE5PSEQvF2=	M1W1WnNCVkeHUh?=
LXF-289	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHmSlRoUUN3ME21MlA{PzF7IN88US=>	M4DnSHNCVkeHUh?=
KINGS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTVwMEe3OFQh\|ryP	NHjYWG9USU6JRWK=
HD-MY-Z	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vXWmlEPTB;NT6yN\|k3QSEQvF2=	NHHqTYZUSU6JRWK=
ESS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPWN246UUN3ME21MlI2PTl5IN88US=>	MmHKV2FPT0WU
GI-1	NFG2dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjreoRKSzVyPUWuNlc6OjZizszN	NEf3O5FUSU6JRWK=
RPMI-2650	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrxeJRKSzVyPUWuN\|YyPiEQvF2=	NFzkUW9USU6JRWK=
IA-LM	NX\MdXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvTNYhTUUN3ME21MlM6QDdzIN88US=>	NXjXU5l1W0GQR1XS
KP-4	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHMOXppUUN3ME21MlQ3OzN2IN88US=>	NYfDbJdFW0GQR1XS
G-402	M4rWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonHTWM2OD13LkWxPFY2KM7:TR?=	MY\TRW5ITVJ?
OS-RC-2	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;pTWM2OD13LkWyOlA1KM7:TR?=	MmjVV2FPT0WU
NCI-H1155	M3jPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDkUWtwUUN3ME21MlU1QTV3IN88US=>	NVfMW3JMW0GQR1XS
OE19	M4rLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjaU3BXUUN3ME21MlY5PjJ2IN88US=>	M3n6V3NCVkeHUh?=
U-2-OS	M2XJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzxZ5JKSzVyPUWuPFkxOTNizszN	NGO0O3RUSU6JRWK=
SCC-15	NIj5UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTVwOUO2OlIh\|ryP	M{XDZ3NCVkeHUh?=
NCI-H630	NFm5cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TZdmlEPTB;NT65PVQxPCEQvF2=	NVixTZlLW0GQR1XS
PFSK-1	NH[4S\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTZwMEWyOVkh\|ryP	NX\NbZM5W0GQR1XS
NCI-H1770	M2ni[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjxfm5KSzVyPU[uNlA5PzRizszN	MXzTRW5ITVJ?
SK-MEL-3	NIjZSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnaTWM2OD14LkSyPVE2KM7:TR?=	MnrGV2FPT0WU
LB1047-RCC	NWDacGdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTZwNEe2NlUh\|ryP	MUnTRW5ITVJ?
NCI-H446	M1Hl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTycWhCUUN3ME22MlYzQTJ3IN88US=>	NF7sWZFUSU6JRWK=
SW780	NEXK[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHGyZ2xKSzVyPU[uO\|AyQDVizszN	NX7EPIYxW0GQR1XS
NEC8	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUe2fGtOUUN3ME22Mlc3PjNizszN	NYLvcY9NW0GQR1XS
NOMO-1	M2T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTZwN{ixNVEh\|ryP	NHTlXFBUSU6JRWK=
COLO-668	NYraSZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTZwOESzPFch\|ryP	NEfpXJFUSU6JRWK=
MC116	M2\h[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\LTWM2OD14LkmzPFk4KM7:TR?=	MVLTRW5ITVJ?
HCC1937	M4LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\oOlJKSzVyPU[uPVkzPTFizszN	NH30ZlFUSU6JRWK=
NCI-N87	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mof4TWM2OD15LkG5Nlk{KM7:TR?=	MUfTRW5ITVJ?
COLO-320-HSR	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fUPWlEPTB;Nz6yNlc{QCEQvF2=	NFr6RnhUSU6JRWK=
HCC1806	M1HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M122SGlEPTB;Nz6yOlA1PCEQvF2=	NHLJ[nBUSU6JRWK=
OVCAR-3	M1WzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7IbVBKSzVyPUeuN\|MxOzhizszN	M4PCd3NCVkeHUh?=
NUGC-3	M3;oWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HmU2lEPTB;Nz6zPVY6PCEQvF2=	NXzFUG1sW0GQR1XS
SW1783	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzkTWM2OD15LkSzNVc2KM7:TR?=	MkLMV2FPT0WU
GCT	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTdwNU[5NFYh\|ryP	NW\k[pdDW0GQR1XS
NCI-H2126	NXzROoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYKz[5ZsUUN3ME23Mlc{PjJ3IN88US=>	NW[3RoJrW0GQR1XS
MEL-HO	NVjUU\|d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjGRY5KSzVyPUeuO\|cxPTRizszN	NIrjdI9USU6JRWK=
CAPAN-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTmTWM2OD15Lke3N\|U4KM7:TR?=	M1naeXNCVkeHUh?=
SW756	M{m2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfzd\|lKSzVyPUeuO\|g{OzNizszN	MljLV2FPT0WU
SKG-IIIa	NYKyd4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzDfodtUUN3ME23MlgyQDl{IN88US=>	MVfTRW5ITVJ?
HCE-T	M{LYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTdwOEe3PFMh\|ryP	MmLTV2FPT0WU
Ca-Ski	M37BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTdwOUmzPFMh\|ryP	MWPTRW5ITVJ?
COLO-684	NWn4eYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrQNmJpUUN3ME24MlAyQDF6IN88US=>	MmjRV2FPT0WU
KYSE-70	NHnWWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTJTWM2OD16LkC3O\|I6KM7:TR?=	M2rRenNCVkeHUh?=
TI-73	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLVN4lKUUN3ME24MlI2QDVzIN88US=>	MYXTRW5ITVJ?
BT-20	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\jfmlEPTB;OD6yOlA2OiEQvF2=	MXrTRW5ITVJ?
MHH-ES-1	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDhUVRKUUN3ME24MlUyQDN2IN88US=>	NVHXUFVrW0GQR1XS
TE-12	NEf2UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn65TWM2OD16LkW5PVMyKM7:TR?=	Moe5V2FPT0WU
YH-13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jD[GlEPTB;OD62NVAxQCEQvF2=	Mn;FV2FPT0WU
SF126	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Hkb2lEPTB;OD64N\|g3PSEQvF2=	M2r4PXNCVkeHUh?=
J82	NX7uN3lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRThwOUCwN\|gh\|ryP	MVHTRW5ITVJ?
RCC10RGB	M{jJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRThwOUm1OlEh\|ryP	MnnrV2FPT0WU
SK-UT-1	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ftZmlEPTB;OT6wOFk1PSEQvF2=	M1W1VXNCVkeHUh?=
LB2241-RCC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX2TWM2OD17LkG5NVM4KM7:TR?=	MYHTRW5ITVJ?
LB996-RCC	M2m5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHTbYlCUUN3ME25MlE6QDlizszN	MXfTRW5ITVJ?
EPLC-272H	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{L5d2lEPTB;OT6zO\|Y2PyEQvF2=	MYfTRW5ITVJ?
CTV-1	NX\jWGZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\FXVBjUUN3ME25MlU3PTN{IN88US=>	NFXUUpFUSU6JRWK=
HSC-2	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zkNGlEPTB;OT61O\|U2KM7:TR?=	M2LBXHNCVkeHUh?=
SK-MEL-28	NFPzUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CzNmlEPTB;OT62NVg6OyEQvF2=	M2\wN3NCVkeHUh?=
MMAC-SF	NXvmWJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jHbGlEPTB;OT62PFc2KM7:TR?=	MmnhV2FPT0WU
CP50-MEL-B	NH\IRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LpeGlEPTB;OT63OVc5OiEQvF2=	NFTlXVhUSU6JRWK=
HT-1080	NWHPVlF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jOS2lEPTB;OT63O\|c{QSEQvF2=	NGTMV\|hUSU6JRWK=
HEC-1	NEPWbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTFyLkOzOVIh\|ryP	MlroV2FPT0WU
AGS	NY\VT5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnv[W5KSzVyPUGwMlM4PCEQvF2=	NIjEWWtUSU6JRWK=
GAMG	M3jhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTFyLkWxOlIh\|ryP	NITPN3lUSU6JRWK=
SW48	NU\1XZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnzZ3hKSzVyPUGwMlUyQDlizszN	MnXvV2FPT0WU
U031	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTFyLkW5NFgh\|ryP	M3LuNHNCVkeHUh?=
OVCAR-5	NYraSIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfQTWM2OD1zMD62OFI6KM7:TR?=	NHH4VXNUSU6JRWK=
SF295	NV;XTI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknKTWM2OD1zMD62O\|A1KM7:TR?=	MU\TRW5ITVJ?
BHT-101	M3nnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zqd2lEPTB;MUCuO\|E4PyEQvF2=	MkHCV2FPT0WU
VMRC-RCZ	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoWwTWM2OD1zMT6zNlAyKM7:TR?=	Moe4V2FPT0WU
ACHN	M1zYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFzLkSyNVEh\|ryP	NHS2TYpUSU6JRWK=
NCI-H526	NEDVWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlH0TWM2OD1zMT61NFQ{KM7:TR?=	M1nSZ3NCVkeHUh?=
MN-60	M4nBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFzLkWzPUDPxE1?	M2\RT3NCVkeHUh?=
NCI-H2291	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTFzLkW0OlYh\|ryP	MVXTRW5ITVJ?
SCC-25	M1PaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTFzLke1OVYh\|ryP	MlLPV2FPT0WU
SK-MEL-2	M4\xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHn[YZKSzVyPUGxMlc3OzdizszN	M1fBcnNCVkeHUh?=
SN12C	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrZTWM2OD1zMT65N\|U2KM7:TR?=	MXPTRW5ITVJ?
NCI-H69	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K2WWlEPTB;MUKuOFI{PCEQvF2=	MlzRV2FPT0WU
ME-180	NIjuVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF{LkewOVQh\|ryP	Mln4V2FPT0WU
MC-IXC	M{\Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;TcWZKSzVyPUGyMlc2OThizszN	Ml[3V2FPT0WU
NCI-H2347	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH2XI5KSzVyPUGyMlc3OTRizszN	Mn7GV2FPT0WU
M059J	NGXyfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr4TWM2OD1zMj63O\|I4KM7:TR?=	Ml;NV2FPT0WU
A2058	NYrTTWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTF{Lki2PFEh\|ryP	M3LZ[HNCVkeHUh?=
VA-ES-BJ	NWXnfY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW2TWM2OD1zMj64O\|g2KM7:TR?=	M4r2TXNCVkeHUh?=
Ca9-22	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPvUoJKSzVyPUGyMlk1PTFizszN	M{HmZnNCVkeHUh?=
KNS-42	NVLSWVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTF{Lkm5PFQh\|ryP	M4\CVHNCVkeHUh?=
LoVo	NEfSToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXhd2F3UUN3ME2xN{4zOzF\|IN88US=>	NFTVRWhUSU6JRWK=
AM-38	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF\|LkK1OlYh\|ryP	MYDTRW5ITVJ?
NB5	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki1TWM2OD1zMz6zO\|UzKM7:TR?=	NGjpeHhUSU6JRWK=
L-363	NXLiTVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF\|LkSwN\|Mh\|ryP	NXK5[FJ5W0GQR1XS
SK-MEL-30	M3LuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXJXZNZUUN3ME2xOE4xPjR3IN88US=>	M1\H[HNCVkeHUh?=
NCI-H1563	NXvBb\|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LVPWlEPTB;MUSuOlA{QSEQvF2=	MlrpV2FPT0WU
NCI-H2228	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\TdGV6UUN3ME2xOE43ODd5IN88US=>	MUHTRW5ITVJ?
MFM-223	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\VcGlEPTB;MUWuNVgyOyEQvF2=	MVjTRW5ITVJ?
LB831-BLC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XGfGlEPTB;MUWuNlc3PyEQvF2=	M{izUXNCVkeHUh?=
SW872	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nXZ2lEPTB;MUWuN\|A5PiEQvF2=	Mo\IV2FPT0WU
NCI-H522	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF3LkOzNFYh\|ryP	MnHNV2FPT0WU
EW-1	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInoeXNKSzVyPUG1MlU1PjJizszN	NV7mbZZYW0GQR1XS
HN	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr3VlJ5UUN3ME2xOU42QTR{IN88US=>	M2LXbHNCVkeHUh?=
SW837	M{HXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF3Lke4OFch\|ryP	NHL6OVVUSU6JRWK=
SCC-9	NWXrb4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTF3LkixNVQh\|ryP	MlHMV2FPT0WU
MKN7	NE\1TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTF3Lkm3N\|Ih\|ryP	NIrVemlUSU6JRWK=
KYSE-410	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD3PYxOUUN3ME2xOk42QTFizszN	NF3i[2hUSU6JRWK=
SK-N-DZ	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmOyTWM2OD1zNj62NVE3KM7:TR?=	MVPTRW5ITVJ?
COR-L105	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrnTWM2OD1zNj62OVI5KM7:TR?=	Mm\rV2FPT0WU
LB2518-MEL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF4LkizPFkh\|ryP	NWnHWpM{W0GQR1XS
OVCAR-4	M2Gycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF4Lki4OlIh\|ryP	NWO1fIN2W0GQR1XS
TK10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTWSm41UUN3ME2xOk46PDd\|IN88US=>	M1HrW3NCVkeHUh?=
KNS-62	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTF4Lkm3O\|ch\|ryP	NIPYO3RUSU6JRWK=
RPMI-8866	NUXtOYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P4[WlEPTB;MUeuNVc{OiEQvF2=	MWLTRW5ITVJ?
HuP-T4	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W2fGlEPTB;MUeuNlQ6PSEQvF2=	M37tWXNCVkeHUh?=
CGTH-W-1	NGPpNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTBbmVKSzVyPUG3MlUzOTlizszN	NV7u[IJNW0GQR1XS
T-24	M2nEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\hTWM2OD1zNz61N\|Q4KM7:TR?=	MmfWV2FPT0WU
HT-3	NGru[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTF5LkW5NVQh\|ryP	NVHy[\|VMW0GQR1XS
KS-1	NGjPVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LPd2lEPTB;MUeuOlc{KM7:TR?=	NVzsfJoyW0GQR1XS
NCI-H1792	NXiyU4htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF5Lke5PEDPxE1?	MYPTRW5ITVJ?
ABC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfXXZRkUUN3ME2xO{45OTRzIN88US=>	NEK4NFlUSU6JRWK=
BPH-1	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG1b2JKSzVyPUG4MlE3QDVizszN	NH\Fe5pUSU6JRWK=
A431	M3WxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF6LkSxNlch\|ryP	NW\3bJlpW0GQR1XS
T98G	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvPeHRXUUN3ME2xPE42OTV5IN88US=>	NE\hd2dUSU6JRWK=
BHY	NFuzZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4S3dGlEPTB;MUiuPFY6KM7:TR?=	MVXTRW5ITVJ?
Capan-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj5TYJKSzVyPUG4MlkxPzhizszN	M4DDb3NCVkeHUh?=
MDA-MB-175-VII	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXvdpBKSzVyPUG4MlkzODlizszN	NGP1V2VUSU6JRWK=
CAL-27	NVjIN29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;1ZmlEPTB;MUmuNFQ5PyEQvF2=	M4LXTXNCVkeHUh?=
AsPC-1	NEPYOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnkfGpXUUN3ME2xPU45PjV5IN88US=>	NFPzbo1USU6JRWK=
KU812	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTF7Lkm1O\|Mh\|ryP	NF63[VVUSU6JRWK=
NCI-H441	NIDnSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Twb2lEPTB;MkCuNFAyKM7:TR?=	NHrOfVZUSU6JRWK=
Mewo	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jySmlEPTB;MkCuNVI5QCEQvF2=	NX\TUpZHW0GQR1XS
SK-MEL-24	NXnjNIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f6VmlEPTB;MkCuNVQ4PyEQvF2=	Mlj4V2FPT0WU
NCI-H727	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTJyLkK3NFQh\|ryP	M1TZeHNCVkeHUh?=
EKVX	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnThTWM2OD1{MD62NFYh\|ryP	MXnTRW5ITVJ?
RT-112	NGf2O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK3RWtTUUN3ME2yNE43OTJ{IN88US=>	NHPMSJdUSU6JRWK=
CAMA-1	M{joZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTJyLkm4NFMh\|ryP	MkKzV2FPT0WU
SW900	M1rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTJzLkCxOFkh\|ryP	NHi4TWpUSU6JRWK=
NCI-H23	NYrQTopnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPYNXVKSzVyPUKxMlEzPzdizszN	MU\TRW5ITVJ?
SK-PN-DW	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvWTWM2OD1{MT6xOlQ6KM7:TR?=	NF3WRlJUSU6JRWK=
BB30-HNC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[2XGlEPTB;MkGuNlc1PSEQvF2=	MmnQV2FPT0WU
VM-CUB-1	NUHXT3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHnTWM2OD1{MT6zOVM3KM7:TR?=	M3W4VXNCVkeHUh?=
IST-MEL1	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUm3SoVvUUN3ME2yNU4{Pjl{IN88US=>	M4LZN3NCVkeHUh?=
CTB-1	NXjSbmwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTJzLkS3OVUh\|ryP	MoDDV2FPT0WU
LCLC-103H	NIPOWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTvTWM2OD1{Mj6xOVgzKM7:TR?=	M1LFUXNCVkeHUh?=
PANC-03-27	NXK0e2llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ{LkWxOlkh\|ryP	NW\uXlhuW0GQR1XS
HTC-C3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfDbpZKSzVyPUKyMlU2PTVizszN	NXjQOVRnW0GQR1XS
TE-8	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnSVohKSzVyPUKzMlI2PjVizszN	MnfQV2FPT0WU
NCI-H292	NULOOXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL6NYVKSzVyPUK1MlM2OzZizszN	MX3TRW5ITVJ?
COLO-680N	M4SzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zPb2lEPTB;MkWuOlMzQSEQvF2=	NVfOcYNxW0GQR1XS
KYSE-520	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTJ3Lk[0OEDPxE1?	NVGweXFSW0GQR1XS
NB10	M130WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XRW2lEPTB;Mk[uN\|EyPyEQvF2=	Mne3V2FPT0WU
NCI-H661	M37KVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJ4LkS3NVMh\|ryP	NUeybYxQW0GQR1XS
GMS-10	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfTc4dKSzVyPUK2Mlg3OzhizszN	MXLTRW5ITVJ?
NCI-H2122	NUL4NXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkGxTWM2OD1{Nj65PVk5KM7:TR?=	M1LSRXNCVkeHUh?=
OVCAR-8	NXH2[XJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjaOmZzUUN3ME2yO{4xPjN6IN88US=>	MWfTRW5ITVJ?
DJM-1	NUfSTVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrpTWM2OD1{Nz6xOFU1KM7:TR?=	MofRV2FPT0WU
UACC-893	NITpN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTwWVJ[UUN3ME2yO{46QDd6IN88US=>	M2OyWHNCVkeHUh?=
C8166	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ6Lk[5N\|gh\|ryP	MWHTRW5ITVJ?
NCI-H1693	MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13vcGlEPTB;MkiuOlk4PSEQvF2=	M1H6SXNCVkeHUh?=
TYK-nu	M{WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHlTWM2OD1\|MD6wN\|Q2KM7:TR?=	NVPOR4p{W0GQR1XS
SW1710	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m3SGlEPTB;M{CuNVI3KM7:TR?=	NITX[W9USU6JRWK=
A375	NEnKSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTNyLkOyOFMh\|ryP	MWPTRW5ITVJ?
HMV-II	NF31W\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fsOmlEPTB;M{GuN\|U6OiEQvF2=	NXzzVnRmW0GQR1XS
NCI-H2087	NF\2UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;EdW94UUN3ME2zNU43OzV{IN88US=>	Mm\sV2FPT0WU
CAL-54	NYfpZnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\lTWM2OD1\|MT63NlQyKM7:TR?=	MYrTRW5ITVJ?
HCC70	NWPiboUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTnTWM2OD1\|Mj6xN\|g4KM7:TR?=	M4TBO3NCVkeHUh?=
ES1	NHLMZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvD[4xWUUN3ME2zNk4{ODZ{IN88US=>	MkWzV2FPT0WU
NCI-H1355	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTJTWM2OD1\|Mz6yNFQh\|ryP	MU\TRW5ITVJ?
CFPAC-1	NHvrcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIe1bodKSzVyPUOzMlI{OzJizszN	M3LI[XNCVkeHUh?=
MKN28	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTN\|LkO4NFkh\|ryP	NInzenBUSU6JRWK=
HDLM-2	NF61S\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTN\|Lk[5N\|Eh\|ryP	MnHTV2FPT0WU
PANC-10-05	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PtcWlEPTB;M{SuNVAyPCEQvF2=	M3fLSXNCVkeHUh?=
SAS	NFP1dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DwfGlEPTB;M{SuOFU3PSEQvF2=	M2HPcXNCVkeHUh?=
HCC1395	M4jDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ryV2lEPTB;M{SuO\|E5PiEQvF2=	M{WwSXNCVkeHUh?=
8305C	NHixPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTN3Lki0NVUh\|ryP	MUTTRW5ITVJ?
KM12	M3nXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv1TWM2OD1\|Nj63OVQ4KM7:TR?=	NGPhUllUSU6JRWK=
SW1116	M336TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTN5LkW5PVIh\|ryP	NWfoVFBJW0GQR1XS
SK-MEL-1	NIXVZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HUNWlEPTB;M{iuN\|M5QSEQvF2=	MnrOV2FPT0WU
HCC2218	M1rUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv6TWM2OD1\|OD62OVE6KM7:TR?=	NWDoRYZuW0GQR1XS
T84	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXrTWM2OD1\|OD63OFA6KM7:TR?=	MnHsV2FPT0WU
ETK-1	M17L[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTN7LkCyNkDPxE1?	M3rKeXNCVkeHUh?=
COLO-800	NGfQNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jvUWlEPTB;M{muN\|g3QCEQvF2=	MUnTRW5ITVJ?
CAL-12T	M1LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u3WGlEPTB;M{muOVI5OSEQvF2=	NImxNFJUSU6JRWK=
ACN	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTRyLkS5NVEh\|ryP	NUT4SW5NW0GQR1XS
SJSA-1	NE\B[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr2foZMUUN3ME20NU4yPTl4IN88US=>	Mn7sV2FPT0WU
PSN1	NHfTOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTRzLkG3OFkh\|ryP	Ml\1V2FPT0WU
D-566MG	NITMTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTRzLkKwPFYh\|ryP	MnPrV2FPT0WU
EGI-1	M{C2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fuSWlEPTB;NEKuOFI5KM7:TR?=	MYLTRW5ITVJ?
A204	M1jhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIP0bplKSzVyPUSyMlY{QDhizszN	M{TPcXNCVkeHUh?=
Saos-2	M2\Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUn0bI1nUUN3ME20Nk45OzZ7IN88US=>	NVjMNo05W0GQR1XS
SNU-C2B	NIq2PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPk[XFMUUN3ME20N{43QDd6IN88US=>	Mn\wV2FPT0WU
HLE	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTR2LkC4OVYh\|ryP	M2rBVXNCVkeHUh?=
SW1463	M2\lXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorxTWM2OD12ND65PVcyKM7:TR?=	NH[1N4pUSU6JRWK=
DSH1	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTR3LkCwN\|Mh\|ryP	MmDmV2FPT0WU
MCF7	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LScGlEPTB;NEWuOVA2OSEQvF2=	MlvnV2FPT0WU
K5	NVfBTIdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nFb2lEPTB;NEWuPVQxPSEQvF2=	MYLTRW5ITVJ?
NCI-H358	NHLlXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXMdWRKSzVyPUS3MlIyPSEQvF2=	MWHTRW5ITVJ?
NCI-H2030	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0SoJKSzVyPUS3MlI{PzRizszN	M134enNCVkeHUh?=
SW948	NXXWNnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfGToljUUN3ME20O{41PjRizszN	NULCVo5HW0GQR1XS
BALL-1	M4fsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nLOWlEPTB;NEeuOlE3QCEQvF2=	M2f0[3NCVkeHUh?=
TE-9	NV7z[XIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoCwTWM2OD12Nz65OVgyKM7:TR?=	Mmf0V2FPT0WU
SK-N-FI	M1T4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXCdVVKSzVyPUS4MlA{PThizszN	MWDTRW5ITVJ?
KALS-1	M3XlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTR6LkGyPFkh\|ryP	Mlj2V2FPT0WU
HO-1-N-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfGOnpKUUN3ME20PE44PDR3IN88US=>	NUPvPYVpW0GQR1XS
NCI-H2452	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLwTWM2OD12OT6xNVUzKM7:TR?=	MULTRW5ITVJ?
OC-314	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W2U2lEPTB;NEmuOlg{PCEQvF2=	M1vCbnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Small Cell Lung Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 28 2017	Phase 1
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2
NCT02520778	Recruiting	EGFR Activating Mutation\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.G719X\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.L861Q\|EGFR NP_005219.2:p.T790M\|Stage III Non-Small Cell Lung Cancer AJCC v7\|Stage IIIA Non-Small Cell Lung Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Non-Small Cell Lung Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Active not recruiting	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02143401	Recruiting	Cirrhosis\|Hepatitis B Infection\|Hepatitis C Infection\|Metastatic Malignant Solid Neoplasm\|Recurrent Hepatocellular Carcinoma\|Recurrent Malignant Solid Neoplasm\|Refractory Malignant Neoplasm\|Stage IV Hepatocellular Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 7 2014	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 38 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 38 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)